Furthermore, targeting cDC1s via CLEC9A neutralizing antibodies effectively inhibited the expansion of AAA in mice, reinforcing the notion that CD8+ T cells are activated by cDC1s to promote AAA progression. The gene discussed is CD8A; the disease is triple-A syndrome.